Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
Alessandro Di Federico, Valentina Tateo, Claudia Parisi, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 7, pp. 677-677
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing
Hao Chi, Songyun Zhao, Jinyan Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 95
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
Alessandro Di Federico, Mirta Mosca, Rachele Pagani, et al.
Cancers (2022) Vol. 14, Iss. 10, pp. 2429-2429
Open Access | Times Cited: 74
Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment
Zhiqing Lin, Keke Huang, Hui Guo, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114567-114567
Open Access | Times Cited: 16
Immunotherapy and Pancreatic Cancer: A Lost Challenge?
Carmelo Laface, Riccardo Memeo, Felicia Maria Maselli, et al.
Life (2023) Vol. 13, Iss. 7, pp. 1482-1482
Open Access | Times Cited: 16
Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment (Review)
Michal Zuzčák, Ján Trnka
International Journal of Oncology (2022) Vol. 61, Iss. 2
Open Access | Times Cited: 25
MicroRNAs and long non-coding RNAs in pancreatic cancer: From epigenetics to potential clinical applications
Luis Alberto Bravo-Vázquez, Natalia Frías-Reid, Ana Gabriela Ramos-Delgado, et al.
Translational Oncology (2022) Vol. 27, pp. 101579-101579
Open Access | Times Cited: 22
Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models
Yuncang Yuan, Jiawei Fan, Dandan Liang, et al.
Translational Oncology (2023) Vol. 39, pp. 101803-101803
Open Access | Times Cited: 13
Role of mast cell in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
Masaaki Nishi, Shoko Yamashita, Chie Takasu, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis
Shunlian Fu, Pingjin Zou, Zengyi Fang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Proteogenomic analysis reveals Arp 2/3 complex as a common molecular mechanism in high risk pancreatic cysts and pancreatic cancer
A. K. M. Firoj Mahmud, Dina Gamaleldin Mansour Aly, Yelin Zhao, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Development of a prognostic model based on four genes related to exhausted CD8+ T cell in triple-negative breast cancer patients: a comprehensive analysis integrating scRNA-seq and bulk RNA-seq
Yulin Shi, Yang Yu, J. Zhao, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Pathogenic mitochondrial dysfunction and metabolic abnormalities
Walter H. Moos, Douglas V. Faller, Ioannis P. Glavas, et al.
Biochemical Pharmacology (2021) Vol. 193, pp. 114809-114809
Open Access | Times Cited: 30
Pancreatic Adenocarcinoma with Co-Occurrence of <i>KRAS</i> and <i>EGFR</i> Mutations: Case Report and Literature Review
J K Mody, Mandana Kamgar
Case Reports in Oncology (2024) Vol. 17, Iss. 1, pp. 399-406
Open Access | Times Cited: 2
Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma
Shiqiong Zhou, Peng Wan, Sen Zhang, et al.
World Journal of Clinical Oncology (2024) Vol. 15, Iss. 7, pp. 859-866
Open Access | Times Cited: 2
Identification of the molecular subtype and prognostic characteristics of pancreatic cancer based on CD8 + T cell-related genes
Dafeng Xu, Yu Wang, Yonghai Chen, et al.
Cancer Immunology Immunotherapy (2022) Vol. 72, Iss. 3, pp. 647-664
Open Access | Times Cited: 11
The association between CD3+ and CD8+tumor-infiltrating lymphocytes (TILs) and prognosis in patients with pancreatic adenocarcinoma
Mahshid Panahi, Fereshteh Rezagholizadeh, Shabnam Mollazadehghomi, et al.
Cancer Treatment and Research Communications (2023) Vol. 35, pp. 100699-100699
Open Access | Times Cited: 6
A Novel 3DNA® Nanocarrier effectively delivers payloads to pancreatic tumors
Grace A. McCarthy, Aditi Jain, Roberto Di Niro, et al.
Translational Oncology (2023) Vol. 32, pp. 101662-101662
Open Access | Times Cited: 6
Clinical Outcome and Prognostic Factors of Pancreatic Adenosquamous Carcinoma Compared to Ductal Adenocarcinoma—Results from the German Cancer Registry Group
Rüdiger Braun, Monika Klinkhammer‐Schalke, Sylke Ruth Zeißig, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 3946-3946
Open Access | Times Cited: 8
The molecular, immune features, and risk score construction of intraductal papillary mucinous neoplasm patients
Xing Huang, Yipeng Feng, Dawei Ma, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 8
Development of a Machine‐Learning Model for Diagnosis of Pancreatic Cancer from Serum Samples Analyzed by Thermal Liquid Biopsy
Sonia Hermoso‐Durán, Nicolás A. Fraunhoffer, Judith Millastre‐Bocos, et al.
Advanced Intelligent Systems (2024)
Open Access | Times Cited: 1
Treatment of pancreatic adenocarcinoma in relation to survival in the U.S. Military Health System
Yvonne L. Eaglehouse, Sarah Darmon, Amie B. Park, et al.
Cancer Epidemiology (2024) Vol. 88, pp. 102520-102520
Closed Access | Times Cited: 1
Long non-coding RNA MIR600HG as a ceRNA inhibits the pancreatic cancer progression through regulating the miR-1197/PITPNM3 axis
Baoming Yang, Zhi-Kai Jiao, Ningning Feng, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24546-e24546
Open Access | Times Cited: 1
CCR7 affects the tumor microenvironment by regulating the activation of naïve CD8+ T cells to promote the proliferation of oral squamous cell carcinoma
Yan Cong, Wei‐Dong Du, Keith L. Kirkwood, et al.
Translational Oncology (2024) Vol. 44, pp. 101924-101924
Open Access | Times Cited: 1
First reported advanced pancreatic cancer with hyperprogression treated with PD-1 blockade combined with chemotherapy: a case report and literature review
Yazhou Wang, Mao-Zhen Peng, Yao-Lin Xu, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Comprehensive Pan-cancer analysis of CD73: explore its association with prognosis and tumor immune microenvironment
Chen Chen, S. Liu, Yanfen Ma
Heliyon (2024) Vol. 10, Iss. 22, pp. e40329-e40329
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top